| Ytd | 85.53% | |
| 1y | 221.76% |
| Open | 76.68 | Prev Close | 76.56 | Low | 75.36 | High | 77.49 | Mkt Cap | 6.79B |
| Vol | 0.00 | Avg Vol | 1.05M | EPS | -2.69 | P/E | -28.64 | Forward P/E | -26.37 |
| Beta | 0.23 | Short Ratio | 9.39 | Inst. Own | 111.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 67.27 | 200-d Avg | 57.71 | 1yr Est | 91.08 |
CGON News
California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON)
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported fin
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorab
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. R
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It m
CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra
CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthu
CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clin
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the d
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the IT
CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologic
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in
CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensu
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial r
The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While emp
